Tempus AI

Tempus AI pioneered the application of artificial intelligence to clinical and molecular data at scale, building one of the world's largest libraries of multimodal health data to help physicians make more informed treatment decisions at the point of care.

Founded in 2015 by Eric Lefkofsky in Chicago, the company grew rapidly by partnering with health systems, academic medical centres, and pharmaceutical companies across the United States and internationally. Its core platform ingests genomic sequencing results, clinical records, imaging, and pathology data, then applies machine learning models to surface insights relevant to individual patient care and broader population-level research.

Tempus operates two closely linked business lines. Its clinical arm provides genomic sequencing and molecular diagnostics services directly to oncologists and other specialists, returning structured, AI-annotated reports alongside raw sequence data. Its life science arm licenses de-identified, longitudinal datasets and analytical tools to pharmaceutical and biotechnology companies conducting real-world evidence studies, biomarker discovery, and clinical trial design and recruitment optimisation.

Oncology has historically been the company's primary focus, where the intersection of genomic complexity and data volume makes AI-driven decision support particularly valuable. Tempus has progressively expanded into cardiology, neuropsychiatry, radiology, and infectious disease, broadening the scope of its data assets and the range of clinical partners it serves.

The company listed on the Nasdaq exchange under the ticker symbol TEM in June 2024, marking one of the more prominent healthcare technology initial public offerings of that year. Its platform, known as the Tempus Intelligence Network, connects data contributors and data consumers in a structure designed to grow in analytical value as participation increases.

Further information is available at tempus.com.